Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

88%

7 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

7(87.5%)

Phase 1

1(12.5%)

8Total

Phase 4(7)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05863832Phase 4Unknown

Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole

Role: lead

NCT05849558Phase 4Unknown

Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

Role: lead

NCT05847205Phase 4Unknown

Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis

Role: lead

NCT04039958Phase 1Completed

A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Role: collaborator

NCT03057574Phase 4Unknown

Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI

Role: lead

NCT01960569Phase 4Unknown

Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas

Role: lead

NCT01896609Phase 4Unknown

Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population

Role: lead

NCT01649245Phase 4Unknown

Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C

Role: lead

All 8 trials loaded